Genistein elicits its anticancer effects through up-regulation of E-Cadherin in Acute Lymphoblastic Leukemia (ALL) cells

An in vitro experimental study

Authors

  • Vahideh Namordizadeh 1 Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Keywords:

Cell lymphoblastic leukemia-lymphoma; Cadherins; Genistein

Abstract

Abstract Background and aim: Genistein is an isoflavone that acts as a potent inhibitor of tyrosine kinase in several cancers. The aim of this study was to elucidate the impact of genistein on leukemia cell lines through E-cadherin signaling pathway.  Methods: This study was conducted in 2016 at the Molecular Medicine Research Center (Hormozgan University of Medical Sciences, Bandar Abbas, Iran). In this in vitro experimental study, the Acute leukemia lymphoma (ALL) cell lines MOLT4 (as mild acute lymphoblastic leukemia cell line) and JURKAT (as high aggressive acute lymphoblastic leukemia cell line) were cultured and then treated with different concentrations of genistein (10, 25, 40 and 55 μM) for 24, 48 and 72 hours. Its cytotoxicity and anti-cancer properties on ALL cell lines were evaluated by calculating the growth rate and MTT assay. Eventually, the effect of genistein on the expression level of E-cadherin was examined using a quantitative Real-Time PCR. In the present research, we used in vitro experimental study.  Results: The percentage of vital malignant cells treated with genistein in comparison with non-treated cells was significantly decreased (p<0.03). E-cadherin expression was significantly (p<0.02) up-regulated between 2 to 4 times as compared with non-treated ones. Even though it seems that genistein induces its anti-cancer properties on all doses, it was found that there is a negative correlation between these anti-cancer properties and increasing the concentration and exposure time of genistein.  Conclusion: The present findings suggest that genistein possesses a growth inhibitory effect on ALL similar to solid tumor cells. It can also be deduced that genistein could be considered as a natural agent to potentially control the invasion of malignant cells and expedition of disease, which is promising and fascinating. From increasing the expression of E-cadherin as a tumor suppressor gene, what it is pioneering in reporting is another mechanism of action of genistein.

References

Silverman LB, Sallan SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic

factors and treatment. Curr Opin Hematol. 2003; 10(4): 290–6. PMID: 12799535.

Rosenquist R. The role of inflammation autoimmune disease and infectious agents in development of

leukaemia and lymphoma. J Intern Med. 2008; 264(6): 512–3. doi: 10.1111/j.1365-2796.2008.02028.x.

PMID: 19017175.

Paixão VA, Vidal DO, Caballero OL, Vettore AL, Tone LG, Ribeiro KB, et al. Hypermethylation of CpG

island in the promoter region of CALCA in acute lymphoblastic leukemia with central nervous system

(CNS) infiltration correlates with poorer prognosis. Leuk Res. 2006; 30(7): 891-4. doi:

1016/j.leukres.2005.11.016. PMID: 16712930.

Tasian SK, Loh ML, Hunger SP. Childhood Acute Lymphoblastic Leukemia: Integrating Genomics Into

Therapy. Cancer. 2015; 121(20): 3577-90. doi: 10.1002/cncr.29573. PMID: 26194091.

Liu X, Li X, Yin L, Ding J, Jin H, Feng Y. Genistein inhibits placental choriocarcinoma cell line JAR

invasion through ERβ/MTA3/Snail/E-cadherin pathway. Oncol Lett. 2011; 2(5): 891-897. doi:

3892/ol.2011.338. PMID: 22866146, PMCID: PMC3408011.

Akiyama T, Ogawara H. Use and Specificity of Genistein as Inhibitor of Protein-Tyrosine Kinases.

Methods Enzymol. 1991; 201: 362-70. doi: 10.1016/0076-6879(91)01032-W. PMID: 1658553.

Wang Y, Wang H, Zhang W, Shao C, Xu P, Shi CH, et al. Genistein sensitizes bladder cancer cells to hcpt

treatment in vitro and in vivo via atm/nf-kb/ikk pathway-induced apoptosis. PLoS One. 2013; 8(1): e50175.

doi: 10.1371/journal.pone.0050175 PMID: 23365634, PMCID: PMC3554754.

Li W, Frame LT, Hoo KA, Li Y, D'Cunha N, Cobos E. Genistein inhibited proliferation and induced

apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro. Leuk

Lymphoma. 2011; 52(12): 2380–90. doi: 10.3109/10428194.2011.598251. PMID: 21749310.

Narasimhan K, Lee YM, Lim TK, Port SA, Han JH, Chen CS, et al. Genistein exerts anti-leukemic effects

on genetically different acute myeloid leukemia cell lines by inhibiting protein synthesis and cell

proliferation while inducing apoptosis – molecular insights from an iTRAQ™ quantitative proteomics

study. Oncoscience. 2015; 2(2): 111-24. PMID: 25859554, PMCID: PMC4381704.

Azarova AM, Lin RK, Tsai YC, Liu LF, Lin CP, Lyu YL. Genistein Induces Topoisomerasae IIbeta- and

Proteasome- Mediated DNA Sequence Rearrangements: Implications in Infant Leukemia. Biochem

Biophys Res Commun. 2010; 399(1): 66–71. doi: 10.1016/j.bbrc.2010.07.043. PMID: 20638367, PMCID:

PMC3376163.

Whittard JD, Craig SE, Mould AP, Koch A, Pertz O, Engel J, et al. E-cadherin is a ligand for integrin a2b1.

Matrix Biol. 2002; 81(5): 525–32. doi: 10.1016/S0945-053X(02)00037-9. PMID: 12392763.

Tsao SW, Liu Y, Wang X, Yuen PW, Leung SY, Yuen ST, et al. The association of E-cadherin expression

and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. Eur J Cancer. 2003;

(4): 524–31. PMID: 12751385.

Coutifaris C, Kao LC, Sehdev HM, Chin U, Babalola GO, Blaschuk OW, et al. E-cadherin expression

during the differentiation of human trophoblasts. Development. 1991; 113(3): 767-77. PMID: 1821848.

Shuna Cui, Juan Wang, Qingqing Wu, Jing Qian, Changshui Yang, Ping Bo. Genistein inhibits the growth

and regulates the migration and invasion abilities of melanoma cells via the FAK/paxillin and MAPK

pathways. Oncotarget. 2017; 21674-91. doi: 10.18632/oncotarget.15535.

Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by

genistein. Oncogene. 1999; 18(20): 3166-72. doi: 10.1038/sj.onc.1202650. PMID: 10340389.

Zhang LL, Li L, Wu DP, Fan JH, Li X, Wu KJ, et al. A novel anti-cancer effect of genistein: reversal of

epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol Sin. 2008; 29(9): 1060–8. doi:

1111/j.1745-7254.2008.00831.x. PMID: 18718175.

Howard L, Parnes MD, William D, Pharm D. Chemoprevention in Prostate Cancer. Pharmacotherapy.

; 57: 1533. doi: 10.1592/phco.26.10.1533.

Severson RK, Nomura AM, Grove JS, Stemmermann GN. A Prospective Study of Demographics, Diet,

and Prostate Cancer among Men of Japanese Ancestry in Hawaii. Cancer Res. 1989; 49(7): 1857-60.

PMID: 2924323.

Maria R, Carmela S, Idolo T, Gian Luigi R. Phytochemicals in Cancer Prevention and Therapy: Truth or

Dare? Toxins. 2010; 2(4): 517-51. doi: 10.3390/toxins2040517. PMID: 22069598.

Carmela S, Gian Luigi R, Ilkay Erdogan O, Solomon H, Maria D, Antoni S, et al. Genistein and Cancer:

Current Status, Challenges, and Future Directions. Adv Nutr. 2015; 6(4): 408–19. doi:

3945/an.114.008052. PMID: 26178025.

Russo M, Gian Luigi A, Daglia M, DeviKasi P, Ravi S, Nabavi SF, et al. Understanding genistein in

cancer: The ‘‘good” and the ‘‘bad” effects: A review. Food Chem. 2016; 196: 589–600. doi:

1016/j.foodchem.2015.09.085. PMID: 26593532.

Henrique B, Eduardo P, Eduardo L, Nathalia C, Rodrigo A, Carina C, et al. Dissecting Major Signaling

Pathways throughout the Development of Prostate Cancer. Prostate Cancer. 2013; 2013: 23. doi:

1155/2013/920612.

Weiqi D, Lei H, Chunlei L, Shumei W, Ping C, Yan Z, et al. Genistein Inhibits Hepatocellular Carcinoma

Cell Migration by Reversing the Epithelial–Mesenchymal Transition: Partial Mediation by the

Transcription Factor NFAT1. Mol Carcinog. 2015; 54(4): 301-11. doi: 10.1002/mc.22100. PMID:

Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia.

NEOPLASIA.2000; 3208-13. PMID: 10807790.

Qian Li, Hong Chen. Epigenetic modifications of metastasis suppressor genes in colon cancer metastasis.

Journal homepage. 2011; 1559-2294. doi: 10.4161/epi.6.7.16314.

Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. Regulatory mechanisms controlling human E- cadherin gene expression. Oncogene. 2005; 24(56): 8277–90. doi: 10.1038/sj.onc.1208991. PMID:

Jalali Nadooshan MR, Davati A, Akhavan F. Expression of E-cadherin in primary breast cancer and and its

correlation with prognosis factors. Shahrekord University of Medical Sciences. 2009; 11(3): 55-60.

Jalali Nadoushan MR, Davati A, Hassanpour M. Relation between E-cadherin expressions in papillary

thyroid carcinoma with some prognostic factors. Quarterly of the Horizon of Medical Sciences. 2014;

(4): 192 -6.

Makoto N, Tsuyoshi S, Hiroshi Y, Ryuichi K. Suppression of gap junctional intercellular communication

via 50 CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells.

Carcinogenesis. 2003; 24(10): 1615-23. doi: 10.1093/carcin/bgg121.

Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-Cadherin Expression Is

Silenced by 5'CpG Island Methylation in Acute Leukemia. Clin Cancer Res. 2000; 6(11): 4243-8. PMID:

Downloads

Published

2021-12-14